

IMPORTANT
MEDICAL INFORMATION
INSIDE

DARATUMUMAB



Telephone contact:

Doctor's Name/Clinic, Center or Hospital Name:

In case of emergency, or if you find this card,
please contact the doctor listed below:

Daratumumab PATIENTS: Provide this card to healthcare providers BEFORE blood transfusion and carry it for 6 months after treatment has ended. For further information please refer to the Patient Information Leaflet

Patient ID Card for DARATUMUMAB

Name: _____

I am taking the following medication:

Daratumumab antibody product for the treatment of multiple myeloma or AL Amyloidosis

I stopped taking this medication on ____/____/____

Dear Healthcare Provider,

Daratumumab is associated with the risk of interference with blood typing. The indirect Coombs test (Indirect antiglobulin test [IAT]) may show positive results in patients taking daratumumab, even in the absence of antibodies to minor blood antigens in the patient's serum which may persist for up to 6 months after the last dose. The determination of a patient's ABO and Rh blood type are not impacted. If an emergency transfusion is required, non-cross-matched, ABO/RHD-compatible RBCs can be given per local blood bank practices.

For more information, please contact local medical information service at Janssen (**placeholder to be completed with country details**) or use this reference as a source of additional information:
<http://online.library.wiley.com/doi/10.1111/itr.13069/epdf>
Additional information on interference with blood compatibility testing can be found on (**placeholder for local website, if available, to be completed with country details**)

Before starting daratumumab my blood test results

collected on ____/____/____ were:

Blood type: ☐ A ☐ B ☐ AB ☐ O ☐ Rh+ ☐ Rh-

Indirect Coombs test (antibody screen) was:

☐ Negative ☐ Positive for the following antibodies:

Other: _____

Contact details of institution where the blood tests were performed: _____

Adverse events reporting guidance:

Ministry of Health and Prevention/Drug Department/Pharmacovigilance and Medical Device section, P.O. Box 1853 Dubai
Telephone 800111111, Email: pv@mohap.gov.ae

Or to Janssen:

Email: GCC-FV2@its.jnj.com, Hotline: +9715598167755